Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Genrix (Shanghai) Biopharmaceutical Co: Clinical Trials & FDA Approval Profile

Genrix (Shanghai) Biopharmaceutical Co (Global / Institutional) sponsors 21 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 10 active protocols (4 recruiting now), 6 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)228 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Genrix (Shanghai) Biopharmaceutical Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)21
Active Pipeline (Recruiting Now)10 (4)
Completed vs Stopped Early6 / 0 (0.0%)
Median Closed Actual Enrollment228 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Genrix (Shanghai) Biopharmaceutical Co
Hospital Research SiteLocationShared Protocols
Zhongnan Hospital of Wuhan UniversityWuhan, Hubei2
The First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, Guangdong2

Explore interactive annual charts and M&A subsidiary rollups in the Genrix (Shanghai) Biopharmaceutical Co Interactive Dossier, benchmark peers in Respiratory and Pulmonary, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI